NASDAQ:AGEN Agenus - AGEN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.55 -0.08 (-3.04%) (As of 01/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.55▼$2.6850-Day Range$2.17▼$3.0452-Week Range$1.25▼$3.37Volume3.45 million shsAverage Volume4.23 million shsMarket Capitalization$777.27 millionP/E RatioN/ADividend YieldN/APrice Target$8.83 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Agenus MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside246.1% Upside$8.83 Price TargetShort InterestBearish6.67% of Shares Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment0.36Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.79) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector604th out of 1,055 stocksBiological Products, Except Diagnostic Industry95th out of 170 stocks 3.5 Analyst's Opinion Consensus RatingAgenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.83, Agenus has a forecasted upside of 246.1% from its current price of $2.55.Amount of Analyst CoverageAgenus has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.67% of the outstanding shares of Agenus have been sold short.Short Interest Ratio / Days to CoverAgenus has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Agenus has recently increased by 4.42%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAgenus does not currently pay a dividend.Dividend GrowthAgenus does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgenus has received a 72.61% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agenus is -0.93. Previous Next 2.4 News and Social Media Coverage News SentimentAgenus has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Agenus this week, compared to 3 articles on an average week.Search Interest35 people have searched for AGEN on MarketBeat in the last 30 days. This is an increase of 192% compared to the previous 30 days.MarketBeat Follows6 people have added Agenus to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agenus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Agenus is held by insiders.Percentage Held by Institutions53.81% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Agenus are expected to grow in the coming year, from ($0.79) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agenus is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agenus is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgenus has a P/B Ratio of 13.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Agenus (NASDAQ:AGEN) StockAgenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.Read More Receive AGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter. Email Address AGEN Stock News HeadlinesJanuary 26, 2023 | finance.yahoo.comAgenus to Participate in February Investor ConferencesJanuary 24, 2023 | seekingalpha.comAgenus' Updated Data Confirms Long-Term Potential ValueJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 23, 2023 | finance.yahoo.comAgenus Presents Clinical Data Demonstrating Durable Responses For Colorectal Cancer CandidateJanuary 23, 2023 | finance.yahoo.comAgenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GIJanuary 21, 2023 | americanbankingnews.comAgenus (NASDAQ:AGEN) Shares Up 3.3%January 18, 2023 | finance.yahoo.com2 Momentum Trades Showing Worst to First ActionJanuary 10, 2023 | finance.yahoo.comAgenus to Participate at B Riley Securities’ 2023 Virtual Oncology ConferenceJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 21, 2022 | finance.yahoo.comAgenus (NASDAQ:AGEN shareholders incur further losses as stock declines 12% this week, taking three-year losses to 42%December 21, 2022 | finance.yahoo.comAgenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GIDecember 12, 2022 | seekingalpha.comAgenus: Perpetually Getting ThereDecember 5, 2022 | msn.comLooking Into Agenus's Return On Capital EmployedDecember 2, 2022 | finance.yahoo.comWhy Shares of Agenus Rose 12.5% on FridayNovember 17, 2022 | finance.yahoo.comAgenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced SarcomaNovember 16, 2022 | finance.yahoo.comAgenus to Participate at 5th Annual Evercore ISI HealthCONx ConferenceNovember 14, 2022 | finance.yahoo.comAgenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant CancersNovember 10, 2022 | finance.yahoo.comAgenus Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 8, 2022 | finance.yahoo.comAgenus (AGEN) Q3 2022 Earnings Call TranscriptNovember 8, 2022 | finance.yahoo.comAgenus Provides Corporate Update and Third Quarter 2022 Financial ReportNovember 8, 2022 | seekingalpha.comAgenus GAAP EPS of -$0.19 in-line, revenue of $22.8M beats by $2.11MOctober 26, 2022 | finance.yahoo.comAgenus (AGEN) to Report Q3 Earnings: What's in the Cards?October 25, 2022 | finance.yahoo.comAgenus (AGEN) Gains But Lags Market: What You Should KnowOctober 25, 2022 | finance.yahoo.comAgenus to Provide Corporate Update and Third Quarter 2022 Financial ReportOctober 18, 2022 | nasdaq.comAgenus (AGEN) Outpaces Stock Market Gains: What You Should Know - NasdaqOctober 18, 2022 | finance.yahoo.comAgenus (AGEN) Outpaces Stock Market Gains: What You Should KnowOctober 13, 2022 | tmcnet.comGSK's older adult RSV vaccine candidate, containingSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter. Email Address AGEN Company Calendar Last Earnings11/08/2022Today1/30/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:AGEN CUSIP00847G70 CIK1098972 Webagenusbio.com Phone(781) 674-4400Fax781-674-4200Employees441Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.83 High Stock Price Forecast$14.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+246.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,930,000.00 Net Margins-249.35% Pretax Margin-249.35% Return on Equity-1,159.04% Return on Assets-50.02% Debt Debt-to-Equity RatioN/A Current Ratio1.45 Quick Ratio1.45 Sales & Book Value Annual Sales$295.67 million Price / Sales2.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book13.42Miscellaneous Outstanding Shares304,810,000Free Float290,181,000Market Cap$777.27 million OptionableOptionable Beta1.33 Key ExecutivesDr. Garo H. Armen Ph.D. (Age 70)Founder, Exec. Chairman & CEO Comp: $1.28MMs. Christine M. Klaskin (Age 57)VP of Fin., Principal Financial Officer & Principal Accounting Officer Comp: $360.51kDr. Steven J. O'Day M.D. (Age 61)Ph.D., Chief Medical Officer Comp: $1.44MDr. Jennifer S. Buell Ph.D. (Age 48)Pres & CEO of MiNK Therapeutics Comp: $917.25kCraig WinterChief Information OfficerRegina Grebla Ph.D.VP of Investor Relations & CommunicationsMs. Robin E. Abrams J.D. (Age 59)Chief Legal Officer Ms. Tracy Mazza ClementeChief People OfficerJohn CastleHead of Translational Medicine & BioinformaticsMs. Julie DeSanderChief Bus. OfficerMore ExecutivesKey CompetitorsNovavaxNASDAQ:NVAXSangamo TherapeuticsNASDAQ:SGMOBioCryst PharmaceuticalsNASDAQ:BCRXExscientiaNASDAQ:EXAIAlectorNASDAQ:ALECView All CompetitorsInsiders & InstitutionsStrs OhioSold 51,900 shares on 1/26/2023Ownership: 0.080%Calamos Advisors LLCBought 11,200 shares on 1/26/2023Ownership: 0.004%Lindbrook Capital LLCBought 1,344,953 shares on 1/25/2023Ownership: 0.442%Allspring Global Investments Holdings LLCSold 23,338 shares on 1/23/2023Ownership: 0.016%Lynch & Associates INBought 17,500 shares on 1/5/2023Ownership: 0.015%View All Institutional Transactions AGEN Stock - Frequently Asked Questions Should I buy or sell Agenus stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGEN shares. View AGEN analyst ratings or view top-rated stocks. What is Agenus' stock price forecast for 2023? 3 analysts have issued twelve-month price objectives for Agenus' shares. Their AGEN share price forecasts range from $5.00 to $14.00. On average, they anticipate the company's stock price to reach $8.83 in the next year. This suggests a possible upside of 246.1% from the stock's current price. View analysts price targets for AGEN or view top-rated stocks among Wall Street analysts. How have AGEN shares performed in 2023? Agenus' stock was trading at $2.40 on January 1st, 2023. Since then, AGEN stock has increased by 6.3% and is now trading at $2.55. View the best growth stocks for 2023 here. When is Agenus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our AGEN earnings forecast. How were Agenus' earnings last quarter? Agenus Inc. (NASDAQ:AGEN) posted its quarterly earnings data on Tuesday, November, 8th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.01. The biotechnology company had revenue of $22.77 million for the quarter, compared to analyst estimates of $19.86 million. Agenus had a negative net margin of 249.35% and a negative trailing twelve-month return on equity of 1,159.04%. What is Garo H. Armen's approval rating as Agenus' CEO? 2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Agenus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include (ROSG) (ROSG), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Gilead Sciences (GILD), Matinas BioPharma (MTNB) and RedHill Biopharma (RDHL). What is Agenus' stock symbol? Agenus trades on the NASDAQ under the ticker symbol "AGEN." Who are Agenus' major shareholders? Agenus' stock is owned by many different institutional and retail investors. Top institutional investors include Lindbrook Capital LLC (0.44%), Strs Ohio (0.08%), Allspring Global Investments Holdings LLC (0.02%), Lynch & Associates IN (0.01%), Calamos Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Corp Incyte, Garo H Armen and Steven J O'day. View institutional ownership trends. How do I buy shares of Agenus? Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Agenus' stock price today? One share of AGEN stock can currently be purchased for approximately $2.55. How much money does Agenus make? Agenus (NASDAQ:AGEN) has a market capitalization of $777.27 million and generates $295.67 million in revenue each year. The biotechnology company earns $-23,930,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. How many employees does Agenus have? The company employs 441 workers across the globe. How can I contact Agenus? Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The official website for the company is agenusbio.com. The biotechnology company can be reached via phone at (781) 674-4400, via email at investor@agenusbio.com, or via fax at 781-674-4200. This page (NASDAQ:AGEN) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.